Genprex Inc GNPX 深 沪
等待开盘 04-01 09:30:00 美东时间
1.81
+0.040
+2.26%
华盛通- 最 高1.82
- 今 开1.73
- 成交量 15.21万股
- 最 低 1.725
- 昨 收 1.77
- 总市值 410.92万
- 52周最高 55.00
- 市盈率 静 --
- 换手率 6.70%
- 52周最低 1.71
- 委 比 44.15%
- 总股本 227.03万
- 历史最高 38900.00
- 量 比 0.79
- 振 幅 5.37%
- 历史最低 1.71
- 每 手 1
- 风险率 5.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers
A Congress member continues to buy small cap stocks. Here's the latest names added to his investment portfolio in March 2026.
03-28 01:10
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR annual meeting
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR annual meeting Genprex said its research collaborators will present preclinical data on Reqorsa gene therapy at the 2026 AACR Annual Meeting on April 17-22, 2026, in San Diego, California. The company said three posters ar
03-18 19:05
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR 2026
Genprex collaborators to present Reqorsa lung cancer preclinical data at AACR 2026 Genprex said its collaborators will present preclinical data on Reqorsa (quaratusugene ozeplasmid) for lung cancer at the 2026 AACR Annual Meeting on April 19, 2026. One poster reports that low TROP2 and high PTEN exp
03-18 19:02
Genprex to Participate at BIO Europe Spring 2026
AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies f...
03-10 19:00
Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer
Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq®
02-23 21:09
Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies
Genprex Wins Japanese and European Patent Grants for Reqorsa Gene Therapy Combinations With PD-1/PD-L1 Immunotherapies Genprex Inc. said the Japanese Patent Office issued a favorable appeal decision to grant a patent covering the use of its Reqorsa gene therapy in combination with PD-L1 antibodies t
02-23 21:01
Genprex erhält Patenterteilungsankündigung für Reqorsa-Gentherapie-Kombination in Australien
Genprex erhält Patenterteilungsankündigung für Reqorsa-Gentherapie-Kombination in Australien Genprex Inc. hat von IP Australia eine Bekanntmachung über die bevorstehende Patenterteilung für die Anwendung der Reqorsa®-Gentherapie in Kombination mit PD-L1-Antikörpern zur Krebsbehandlung erhalten. Das
02-10 21:02
Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment
Genprex Announces IP Australia's Acceptance of Patent Application for Reqorsa® Gene Therapy and PD-L1 Antibody Combination in Cancer Treatment Genprex Inc. announced that IP Australia has issued a Notice of Acceptance for its patent application covering the use of Reqorsa® Gene Therapy in combinatio
02-10 21:02
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
Genprex Announces Preliminary in Vivo Preclinical Proof-of-concept Data for GPX-002 Diabetes Gene Therapy Drug Candidate, in a Non-human Primate Model and Mouse Model of Type 2 Diabetes
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human PrimatesGPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2
01-06 20:04
